CLINICAL ROLE -
July 30th 2025
Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.
June 30th 2025
Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for routine screening.
Ropeginterferon alfa-2b shows promising results in treating preprimary myelofibrosis, enhancing clinical responses and safety in patients.
INCB057643 shows promise in treating myelofibrosis, enhancing anemia and symptom relief.
June 3rd 2025
Explore the latest advancements in myelofibrosis treatment, focusing on JAK inhibitors and pegylated interferons for improved patient outcomes.